[ Inside the business ]

ASPI stock analysis

ASPI · Asp Isotopes Inc.

Miscellaneous chemical products. Growing 303%. Loses 359¢ on every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.0× sales in 5 yrs. Evidence: sales +303% · loss shrinking · Advanced nuclear fuel (HALEU) rising.

01 What's priced in?2.0× sales in 5 yrs
Sales now$35M
Needed in 5 yrs$69M
02 Is the wave rising?Advanced nuclear fuel (HALEU) · 1.6×
'20'21'22'23'24'2511
#2 of 20 mentioning it
03 Will customers keep buying?Customer: 32% of sales
Customer 32%Customer One 14%Everyone else
Sales +303%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss shrinking: −$3.6 per $1
'23'24'25−$3.6
Before running costs: 0% → 14%
06 Can it fund itself?2.0 yrs of cash
05 yrs10+ yrs
Shares +49.1%/yrDebt $53M
07 What could break it?3 to watch
  • Growth peaked
  • Heavy dilution
  • Moves strongly with the Credit spreads widen 1 pt

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +279%, +328%, then +303% vs. a year ago.

What could go wrong

Red flags.

It has moved 3.7× the market. Debt is covered by cash. 1 red flag in its filings.

Speculative check

Speculative.

Speculative: operating loss, cash flowing out of operations, under $1B in sales. Cash runway: 2.0 years.

What they sell

76% Construction.

Construction 76% · Products 24%

Where each dollar goes

359¢ loss.

82¢ to make what it sells, 377¢ on research and overhead, nothing left over. Revenue $35M in the last 12 months.

Its market

1.1× the economy.

The government expects its industry, chemical manufacturing, to grow 2.2% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Introduction.

It uses cash, invests, and raises money to keep going.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

0 of 4 years.

Returns beat its 16.2% cost of capital in 0 of the last 4 years. Gross margin went from 0% to 14%.

Future bets

75% on research.

$26M a year on R&D. $16M on equipment and buildings.

All figures from Asp Isotopes Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.